SFDA Bans Cash Transactions For Formulations Containing Controlled Substances
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has issued a notice on tightening sales of formulations containing controlled substances to curb illicit extracts from formulated compounds which do not come under controlled drugs. Drug producers or distributors will be banned from cash transactions for some compound formulations, including those containing ephedrine, oral solutions containing codeine, diphenoxylate compound tablets and liquorice compound tablets. According to the notice, all companies with medicine trading licenses can operate the compound formulation business; however drug producers or distributors must file accounts information, and issue or ask for sales receipts when dealing with drugs. Wholesalers or firms that make the compound formulations directly for illegal drug producers will have their licenses revoked, and also face additional penalties. (Click here for more - Chinese Language)
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.